These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33085755)

  • 21. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
    Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields P; Gunawan A; Oliver R; Djebbari F; Booth S; McMillan A; Fox CP; Bishton MJ; Collins GP; Hatton CSR
    J Intern Med; 2019 Jun; 285(6):681-692. PubMed ID: 30811713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine particulate matter and cause-specific mortality in the Hong Kong elder patients with chronic kidney disease.
    Ran J; Sun S; Han L; Zhao S; Chen D; Guo F; Li J; Qiu H; Lei Y; Tian L
    Chemosphere; 2020 May; 247():125913. PubMed ID: 31962222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register.
    Cheng F; Luk AO; Tam CHT; Fan B; Wu H; Yang A; Lau ESH; Ng ACW; Lim CKP; Lee HM; Chow E; Kong AP; Keech AC; Joglekar MV; So WY; Jenkins AJ; Chan JCN; Hardikar AA; Ma RCW
    Diabetes Care; 2020 Sep; 43(9):2257-2265. PubMed ID: 32661111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City.
    Park BE; Lee JH; Park HK; Kim HN; Jang SY; Bae MH; Yang DH; Park HS; Cho Y; Lee BY; Nam CW; Lee JB; Kim U; Chae SC;
    J Korean Med Sci; 2021 Jan; 36(2):e15. PubMed ID: 33429474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study.
    Hung YM; Chang WP; Wei JC; Chou P; Wang PY
    Medicine (Baltimore); 2016 May; 95(18):e3596. PubMed ID: 27149491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High risk for cardiovascular disease in Chinese type 2 diabetic patients with major depression--a 7-year prospective analysis of the Hong Kong Diabetes Registry.
    Ting RZ; Lau ES; Ozaki R; Lau WW; Kong AP; Luk AO; Chow CC; Ma RC; Wing YK; Chan JC; So WY
    J Affect Disord; 2013 Jul; 149(1-3):129-35. PubMed ID: 23399477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
    Booth S; Plaschkes H; Kirkwood AA; Gibb A; Horgan P; Higham C; Oladipo JM; Browning J; Khan U; Tseu B; Chen L; Willan J; Wolf J; Gunawan A; Fields P; Ebsworth T; Lown R; Gordon-Walker D; Shah N; Linton KM; Collins GP; Kothari J; Hildyard C; Eyre TA
    Blood Adv; 2020 Sep; 4(18):4337-4346. PubMed ID: 32915975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
    Xiao DY; Luo S; O'Brian K; Sanfilippo KM; Ganti A; Riedell P; Lynch RC; Liu W; Kahl BS; Cashen AF; Fehniger TA; Carson KR
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
    Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.
    Visco C; Pregnolato F; Ferrarini I; De Marco B; Bonuomo V; Sbisà E; Fraenza C; Bernardelli A; Tanasi I; Quaglia FM; Krampera M
    Crit Rev Oncol Hematol; 2021 Jul; 163():103377. PubMed ID: 34087342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.
    Armenian SH; Xu L; Ky B; Sun C; Farol LT; Pal SK; Douglas PS; Bhatia S; Chao C
    J Clin Oncol; 2016 Apr; 34(10):1122-30. PubMed ID: 26834065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term exposure to air pollution and mortality in an elderly cohort in Hong Kong.
    Yang Y; Tang R; Qiu H; Lai PC; Wong P; Thach TQ; Allen R; Brauer M; Tian L; Barratt B
    Environ Int; 2018 Aug; 117():99-106. PubMed ID: 29730535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.